$SRDX (SurModics, Inc.)

$SRDX {{ '2016-01-08T13:07:19+0000' | timeago}} • Announcement

Medical device maker $SRDX said it lifted its FY16 revenue guidance to about $60.0-64.0MM from $56.0-60.0MM. The GAAP earnings is now expected to be about $0.38-0.43 per share vs $0.70-0.80 per share announced previously. $SRDX expects the non-GAAP earnings to be about $0.66-0.75 per share.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$HAE {{ '2017-10-18T15:38:09+0000' | timeago}} • Announcement

$HAE elected Robert Abernathy to its BoD. Abernathy has led major medical businesses in North America and Europe with Halyard Health, Inc. Abernathy served as Chairman of the Board and CEO of Halyard Health Inc., a $KMB spinoff medical technology company specializing in important patient health care needs.

$HAE {{ '2017-10-18T15:03:18+0000' | timeago}} • Announcement

$HAE elected Robert Abernathy to its BoD. Abernathy previously served on the Board of The Advanced Medical Technology Association (AdvaMed).

$REGN {{ '2017-10-16T14:56:28+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from a Phase 2 study of dupilumab in adults with active moderateto-severe eosinophilic esophagitis (a condition that causes swallowing difficulty). The study showed that patients who received dupilumab weekly reported a significant improvement in the ability to swallow versus placebo.

$REGN {{ '2017-10-16T13:04:52+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing and food impaction.

$RMD {{ '2017-10-12T15:04:09+0000' | timeago}} • Announcement

$RMD announced that the Munich District Court decided that ResMed's AirSense 10, AirCurve 10, Lumis and their humidifiers do not infringe a Fisher & Paykel German utility model patent. This ruling in Germany has no impact on ResMed and Fisher & Paykel's patent infringement litigation in other jurisdictions.

$HRC {{ '2017-10-11T12:47:11+0000' | timeago}} • Announcement

$HRC provided an update on its Aspen Surgical facility in Las Piedras, Puerto Rico, where the company manufactures Bard-Parker surgical scalpels and blades. The company confirmed that the facility sustained minor structural damage, temporary loss of power and minimal water damage due to Hurricane Maria.

$CRY {{ '2017-10-10T21:57:05+0000' | timeago}} • Announcement

In connection with the JOTEC transaction, $CRY has terminated its relationship with some of its distributors. Due to this, $CRY will buy back a portion of the inventory previously sold to these distributors, which will result in a $1.1MM reversal of revenues. Considering this and aforementioned factors, preliminary 3Q17 revenues were approx. $44MM.

$CRY {{ '2017-10-10T21:56:48+0000' | timeago}} • Announcement

$CRY said 3Q17 revenues were adversely affected due to the impact of the recent hurricanes on its business in Florida and Texas, which is estimated to be approx. $1MM, and additionally due to the continued delay in obtaining the re-certification of AAP. Including the impact of these factors, 3Q17 revenue was approx. $45.1MM.

$CRY {{ '2017-10-10T21:56:25+0000' | timeago}} • Announcement

$CRY will acquire JOTEC AG. $CRY expects the acquired portfolio to post double-digit growth outside the US for at least the next five years. The deal will also drive GM expansion and help deliver 20% or higher operating margins. $CRY believes it will be able to deliver adjusted EPS growth at a CAGR of at least 20% over the next five years.

$CRY {{ '2017-10-10T21:56:09+0000' | timeago}} • Announcement

$CRY has agreed to acquire German-based company JOTEC AG for $225MM, consisting of 75% in cash and 25% in CryoLife common stock issued to JOTEC's shareholders. $CRY expects to finance the transaction as well as refinance its existing $69MM term loan, with new $255MM senior secured credit facilities. The deal is expected to close later in 2017.

$HRC {{ '2017-10-10T14:13:09+0000' | timeago}} • Announcement

$HRC's Welch Allyn subsidiary said its home medical devices will now be offered as part of $HON’s remote patient monitoring platform. The Welch Allyn Home 1700 Series Blood Pressure Monitor and Welch Allyn Home Weight Scale will be offered as standard peripherals with Honeywell Life Care Solution's Genesis Touch remote patient monitoring kits.

$REGN {{ '2017-10-05T17:28:07+0000' | timeago}} • Announcement

Sanofi and $REGN said the U.S. Court of Appeals for the Federal Circuit has ordered new trial and vacated permanent injunction in the dispute concerning $AMGN's asserted patent claims for antibodies targeting PCSK9. This ruling means that Sanofi and $REGN will continue marketing, selling and manufacturing Praluent (alirocumab) injection in the U.S.

$HRC {{ '2017-10-05T12:06:47+0000' | timeago}} • Announcement

Chairman of $HRC Board Rolf Classon will not stand for re-election to the BoD when his current term expires on March 6, 2018. The Board plans to appoint current independent director William Dempsey to this role if he is re-elected by shareholders. The company also elected Gary Ellis, retired CFO and SVP of $MDT, to its BoD, effective Oct 5, 2017.

$TFX {{ '2017-10-02T20:23:51+0000' | timeago}} • Announcement

$TFX completed the acquisition of NeoTract, Inc. for $1.1Bil. Under the terms of the agreement, $TFX acquired NeoTract for an upfront cash payment of $725MM at closing, and has agreed to pay up to an additional $375MM upon the achievement of certain commercial milestones related to sales through the end of 2020.

$CRY {{ '2017-10-02T12:50:21+0000' | timeago}} • Announcement

$CRY announced the appointment of Jeffrey Burbank to its BoD, effective Sept 29, 2017. Burbank is the CEO and founder of $NXTM.

$REGN {{ '2017-10-02T12:04:30+0000' | timeago}} • Announcement

Pharma company $REGN has entered into collaborations with the Biomedical Advanced Research & Development Authority to develop  treatments for infectious diseases. The first collaboration is focused on development of antibodies targeting up to 10 pathogens, while the second builds on a prior agreement to develop a potential therapy for Ebola virus.

$REGN {{ '2017-09-28T12:24:36+0000' | timeago}} • Announcement

$REGN and $SNY have announced that the European Commission has granted marketing authorization for DUPIXENT (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. AD, a form of eczema, is a chronic inflammatory disease with symptoms often appearing as a rash on the skin.

$REGN {{ '2017-09-18T10:59:56+0000' | timeago}} • Announcement

Pharma company $REGN and healthcare firm $SNY said a study showed that Dupixent, which is indicated for the treatment of atopic dermatitis, significantly improved overall disease severity. It also met the primary end point - the proportion of patients that achieved a 75% or greater improvement at 16 weeks from baseline.

Recent Transcripts

PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
SRDX (SurModics, Inc.)
Thursday, August 3 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, August 3 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, August 2 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm

AlphaGraphics you may like